Lim HH• Dulaglutide in juvenile T2DM 236 www. e-apem. org insulin, with no serious
adverse events. 10) The current study is the first report to determines the effects and side …

Purpose We sought to investigate the effects and side effects of once-weekly dulaglutide
treatment for type 2 diabetes mellitus (T2DM) in patients< 18 years of age in Korea …

Background The incidence of type 2 diabetes mellitus is increasing among youths. Once-
weekly treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist, may have …

AWARD-PEDS was a Phase 3 trial to assess the efficacy and safety of dulaglutide (DU), a
once-weekly GLP-1 receptor agonist, in youth (10 to< 18 years old) with T2D treated with …

Prior to the SEARCH for Diabetes in Youth, a large multicenter study that described the
prevalence of diabetes in the pediatric population, type 2 diabetes (T2DM) was mainly …

In 855 Japanese patients with type 2 diabetes receiving once weekly dulaglutide 0.75 mg in
3 phase 3 studies, the effects on efficacy and safety at week 26 (last observation carried …

This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide
therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients …

We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2
randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52 …

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained traction for the
management of type 2 diabetes and obesity. Unlike several classes of antidiabetic …

Background To investigate the real-world safety and effectiveness of dulaglutide in Korean
adults with type 2 diabetes mellitus (T2DM). Methods This was a real-world, prospective …